Journal article

Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders - A systematic critical reappraisal

Mario Alvarez-Jimenez, Cesar Gonzalez-Blanch, Benedicto Crespo-Facorro, Sarah Hetrick, Jose Manuel Rodriguez-Sanchez, Rocio Perez-Iglesias, Jose Luis Vazquez-Barquero

CNS DRUGS | ADIS INT LTD | Published : 2008

Abstract

Antipsychotic-induced weight gain is an important issue in the treatment of psychotic illnesses, and affects 80% of individuals being treated with antipsychotic drugs. However, the true dimension of weight gain and many accepted 'facts' in this area remain unclear as most research has been conducted in short-term trials and has included individuals receiving prolonged antipsychotic treatment. This review aims to systematically and critically review the evidence on weight gain induced by the two leading second-generation antipsychotics (olanzapine and risperidone) and the most widely researched first-generation antipsychotic (haloperidol) in patients with chronic and first-episode psychotic d..

View full abstract